164 related articles for article (PubMed ID: 15628041)
1. [Lung function and exercise tolerance after treatment with salmeterol or ipratropium bromide in chronic obstructive pulmonary disease].
Grzanka A; Pitsch T; Krzywiecki A; Rogala B
Pol Merkur Lekarski; 2004 Sep; 17(99):208-11. PubMed ID: 15628041
[TBL] [Abstract][Full Text] [Related]
2. A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.
Balkissoon R; Make B
COPD; 2008 Aug; 5(4):221-7. PubMed ID: 18671147
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary diseases.
Gupta RK; Chhabra SK
Indian J Chest Dis Allied Sci; 2002; 44(3):165-72. PubMed ID: 12206475
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD.
O'Donnell DE; Laveneziana P; Ora J; Webb KA; Lam YM; Ofir D
Thorax; 2009 Mar; 64(3):216-23. PubMed ID: 19052054
[TBL] [Abstract][Full Text] [Related]
5. Effects of tiotropium or combined therapy with salmeterol on hyperinflation in COPD.
Eguchi Y; Tateishi Y; Umeda N; Yoshikawa T; Kamoi H; Kanazawa H; Kudoh S; Hirata K; Fujimoto S
Osaka City Med J; 2007 Jun; 53(1):25-34. PubMed ID: 17867631
[TBL] [Abstract][Full Text] [Related]
6. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen.
Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM
Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734
[TBL] [Abstract][Full Text] [Related]
7. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
8. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
[TBL] [Abstract][Full Text] [Related]
9. Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD.
Corda L; Bertella E; La Piana GE; Boni E; Redolfi S; Tantucci C
Respiration; 2008; 76(1):61-8. PubMed ID: 18319586
[TBL] [Abstract][Full Text] [Related]
10. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance.
Donohue JF; Hanania NA; Sciarappa KA; Goodwin E; Grogan DR; Baumgartner RA; Hanrahan JP
Ther Adv Respir Dis; 2008 Apr; 2(2):37-48. PubMed ID: 19124357
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease.
Patakas D; Andreadis D; Mavrofridis E; Argyropoulou P
Respir Med; 1998 Sep; 92(9):1116-21. PubMed ID: 9926165
[TBL] [Abstract][Full Text] [Related]
12. [Relation between pulmonary ventilation parameters, exercise tolerance and quality of life in patients with chronic obstructive lung disease].
Chlumský J; Stĕrbová L; Smolíková L; Matous M; Salajka F
Vnitr Lek; 2002 Apr; 48(4):320-4. PubMed ID: 12061182
[TBL] [Abstract][Full Text] [Related]
13. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
Singh D; Brooks J; Hagan G; Cahn A; O'Connor BJ
Thorax; 2008 Jul; 63(7):592-8. PubMed ID: 18245142
[TBL] [Abstract][Full Text] [Related]
14. The effect of bronchodilators and oxygen alone and in combination on self-paced exercise performance in stable COPD.
Cukier A; Ferreira CA; Stelmach R; Ribeiro M; Cortopassi F; Calverley PM
Respir Med; 2007 Apr; 101(4):746-53. PubMed ID: 17000096
[TBL] [Abstract][Full Text] [Related]
15. Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?
Akkoca Yildiz O; Onen ZP; Demir G; Eriş Gülbay B; Saryal S; Karabiyikoğlu G
Tuberk Toraks; 2006; 54(2):105-13. PubMed ID: 16924565
[TBL] [Abstract][Full Text] [Related]
16. Endurance shuttle walking test: responsiveness to salmeterol in COPD.
Brouillard C; Pepin V; Milot J; Lacasse Y; Maltais F
Eur Respir J; 2008 Mar; 31(3):579-84. PubMed ID: 18057052
[TBL] [Abstract][Full Text] [Related]
17. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.
Tashkin DP
Am J Med; 2006 Oct; 119(10 Suppl 1):63-72. PubMed ID: 16996901
[TBL] [Abstract][Full Text] [Related]
18. [Effect of ipratropium bromide on lung dynamic hyperinflation in patients with chronic obstructive lung disease].
Jorquera J; Díaz O; Lisboa C
Rev Med Chil; 2003 Jun; 131(6):605-12. PubMed ID: 12942587
[TBL] [Abstract][Full Text] [Related]
19. Locus of symptom limitation and exercise response to bronchodilation in chronic obstructive pulmonary disease.
Deschênes D; Pepin V; Saey D; LeBlanc P; Maltais F
J Cardiopulm Rehabil Prev; 2008; 28(3):208-14. PubMed ID: 18496322
[TBL] [Abstract][Full Text] [Related]
20. Quality of life measurements and bronchodilator responsiveness in prescribing nebulizer therapy in COPD.
Brophy C; Kastelik J; Gardiner E; Greenstone M
Chron Respir Dis; 2008; 5(1):13-8. PubMed ID: 18303097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]